ArticleBMC cancer2026
The predictive value of the lymphocyte-C-reactive protein ratio for early recurrence in MVI positive HCC patients who underwent postoperative adjuvant transcatheter arterial chemoembolization.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIn this study, we evaluated the prognostic capacity of the lymphocyte-to-C-reactive protein ratio (LCR) in predicting one-year recurrence among patients with microvascular invasion (MVI)-positive hepatocellular carcinoma (HCC) who underwent postoperative adjuvant transarterial chemoembolization (PA-TACE).
methodsA total of 480 HCC patients were retrospectively enrolled in this single-center study. Among them, 146 patients with MVI-positive HCC underwent PA-TACE. The LCR was calculated prior to surgery using the formula: LCR = 104 × lymphocyte count (109/L) / C‑reactive protein (mg/L). The predictive value of LCR for early recurrence was assessed using LASSO regression, along with univariate and multivariate Cox regression analyses. A prognostic model was subsequently developed and validated through decision curve analysis (DCA) and receiver operating characteristic (ROC) curve analysis.
resultsIn the nomogram model, an LCR value below 11,000 (≤ 11,000 vs. > 11,000; HR = 3.268, 95% CI: 1.346–7.936, P = 0.009) was associated with worse 1-year RFS in HCC patients who underwent PA-TACE. The nomogram also incorporated additional prognostic variables: alpha-fetoprotein (AFP) > 20 ng/mL (> 400 vs. ≤ 20; HR = 2.635, 95% CI: 1.255–5.532, P = 0.010), tumor diameter (HR = 1.153, 95% CI: 1.053–1.253, P = 0.002), ALT level (HR = 0.359, 95% CI: 0.179–0.718, P = 0.004), and MVI class (class 2 vs. class 1; HR = 2.438, 95% CI: 1.344–4.422, P = 0.003). The combined nomogram demonstrated a satisfactory discriminative ability, with a concordance index of 0.759 (95% CI: 0.694–0.825). Furthermore, time-dependent ROC analysis confirmed the model’s predictive accuracy, yielding an AUC of 0.788 (95% CI: 0.714–0.863). Both time-dependent ROC and decision curve analyses supported the clinical utility of the nomogram for recurrence risk stratification.
conclusionsLCR is an important prognostic factor for early recurrence in MVI-positive HCC patients who received PA-TACE. Our nomogram model combining LCR shown sufficient discrimination ability and ideal prediction capability to distinguish patients at risk for early recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.